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ABSTRACT 
 
Development of a biomarker-based prediction model of disease progression 
during chemotherapy in children and adolescents 
 
Young-A Heo 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Kyungsoo Park) 
 
Aims: This study aims to develop a quantitative semi-mechanistic model to describe 
the disease progression of leukemia during chemotherapy using circulating 
biomarkers in Korean children and adolescent population.   
 
Methods: A routine clinical data set for 74 patients who were diagnosed as acute 
lymphoblastic leukemia (ALL) for the first time between the age of 1 – 19 were 
collected from Severance hospital electric medical records (EMR) system. Absolute 
lymphocyte count (ALC) and platelet count (PLT) were dependent variables. Age, 
WBC count, bone marrow transplantation (BMT) and other laboratory results such 
as creatinine, AST and ALT levels were possible covariates to be tested. A (semi) 
mechanistic model was used to describe ALC and PLT changes with time during 
chemotherapy. A K-PD model was used to describe drug kinetics as blood 
concentration data were not available. ALC and PLT production were described by a 
３ 
 
single compartment representing proliferative cells, 3 transit compartments 
representing biomarker maturation, and a single compartment representing biomarker 
concentrations in blood, where ALC production was assumed to be positively 
influenced by linear disease progression of ALL and reduced by chemotherapy and 
vice versa for PLT. Covariate search was then carried out for biomarkers. Population 
modeling approach was performed using NONMEM 7.3. 3 year overall survival 
analysis was performed using variables from biomarker disease progression models 
as predictors of overall survival of ALL patients.  
 
Results: Due to data’s heterogeneity, patients treatment options were grouped into 
risk based protocol, standard risk (SR) and high risk (HR) based on the clinical 
practice. Drug effect was described by an Emax model of effect-site concentration 
obtained from K-PD model, where drug doses were BSA standardized due to the use 
of multiple cytotoxic drugs during the treatment. In addition, chemotherapy resistance 
was described the best with inhibitory Imax model where the chemotherapy exposure 
inhibits the drug effect. Estimated EC50 of standard and high risk groups are 0.00026 
and 0.711 respectively in ALC, and 1.57 and 3.1 respectively in PLT. Estimated mean 
transit time (MTT) was 5.34 days and 17.0 days for lymphocyte and platelet 
respectively. Estimated gamma for ALC and PLT were 0.0973 and 0.215 respectively, 
which denotes the power of feedback component. For 3 year survival analysis of ALL 
patients, predicted latent disease slope of PLT at day 30 (DPLT), history of bone 
marrow transplantation (BMT) and predicted ALC/baseline ratio averaged over the 
period of day 1 to day 22 (RALC) were statistically significant predictors of 3 yr 
survival time in ALL patients in children and adolescents.   
 
Conclusion: The proposed semi-mechanistic disease progression model with 
circulating biomarkers provide platforms to predict survival time of ALL patients 
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which can be a powerful tool to help clinicians to monitor disease in ALL patients in 
children and adolescents.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                    
Keywords: acute lymphoblastic leukemia, biomarker, disease progression model, 
platelet counts, absolute lymphocyte counts, clinical data   
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I. INTRODUCTION  
 
1. Pharmacokinetic-pharmacodynamic (PKPD) 
modeling in oncology 
In recent years, development of individualized therapies for oncology patients 
became the key objective to enhance efficacy.1 By doing so, it is hoped that the 
individualized therapy would be able to predict a clinical outcome from an early stage 
when the patients were given existing or newly developed treatment.1 Unfortunately, 
the difficulty lies in the various factors influencing outcome such as treatment 
efficacy, toxicity and development of resistance and the limited predictive ability of 
current monitoring techniques.2 
 
For cancer patients, extending overall survival (OS) is considered to be the most 
preferred endpoint to examine treatment benefit but collecting OS data may take years 
before drawing statistical conclusion. As a result, drug development is often based on 
an improvement in progression free survival (PFS).2 Population PKPD modeling has 
become a key tool in drug development including oncologic drugs to understand, 
identify and quantify various dose-response relationships. 2 The modeling techniques 
provide platform to predict the time course of the drug effect with the aim to optimize 
dosing2,3 and links the drug effect to tumor growth dynamics. By doing so, it can be 
used to discriminate drug effects from degenerative disease.2,4 In addition, PKPD 
modeling can describe between subject variability and quantitatively account for 
covariate influence thus drug effect on the disease can be evaluated more precisely.  
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After all, developed PKPD models in clinical oncology may aid clinicians to 
individualize drug treatment scheme and industry to design clinical trials towards 
minimizing drug toxicity and optimize drug efficacy through establishing optimal 
dose, regimen for individual patient.  
 
2. Role of biomarkers in oncology  
Recently, applying circulating biomarkers that are known to be related to the 
pathophysiology of cancer to quantitatively predict the clinical outcome is proposed 
as an alternative approach.1-3 Circulating biomarkers are fairly easy to obtain from 
peripheral blood and can be used in conjunction with conventional diagnostic method 
and procedure such as RECIST.1 Despite the fact that proof of concept regarding the 
use of biomarkers is well-established in drug development,2,3 use of biomarkers to 
evaluate the treatment response is seldom applied in clinical practice possibly due to 
inadequate validation of biomarkers.  
 
Therefore, in order to properly assess the utility of biomarkers, assessments should 
be made in the context of longitudinal models linking their observed levels with 
clinical outcome in a timely manner. Recently, few studies showed the feasibility of 
the use of longitudinal models with (semi) mechanistic approaches.1,5-10 There have 
been approaches to develop population modeling of tumor size or tumor markers to 
assess the efficacy of oncologic drugs on cancer.1,4,7-10  
 
Hansson et al successfully developed the population disease progression model to 
predict the change in tumor size by using longitudinal biomarker as one of predictors 
of tumor dynamics in gastrointestinal stromal tumors (GIST), receiving sunitinib 
and/or placebo treatment.9 Buil-Bruna et al developed a population 
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pharmacodynamics model to predict the tumor progression in Small Cell Lung 
Cancer (SCLC) patients using lactate dehydrogenase (LDH) and neuron specific 
enolase (NSE).1 The developed model comprised of two parts, disease level and 
biomarkers turnover models and one of the key assumptions for the model is that the 
progression of the diseases promotes the synthesis of LDH and NSE. On the other 
hand, Desmee et al demonstrated that complex and physiological models can be used 
to improve treatment evaluation and prediction in oncology. The literature suggested 
the idea by developing joint model that determines the relationship between time to 
event and PSA kinetics mechanistically.10  
 
3. Acute lymphoblastic Leukemia (ALL)  
ALL is a malignant disease of the bone marrow where early lymphoid precursors 
proliferate and replace the normal hematopoietic cells of the marrow.11 It is the most 
common cancer among children and adolescents.11 Patients with ALL commonly 
present with symptoms including bleeding due to thrombocytopenia and fatigue from 
anemia.11 The disease could be of B-cell precursor or T-cell lineage and patients with 
T-cell lineage shows inferior survival among children and adolescents.  
 
Childhood ALL generally comprises multiple genetic alterations including 
aneuploidy or DNA sequence mutations. These mutations commonly target genes 
encoding proteins that are involved in tumor-suppressor functions, lymphoid 
differentiation and cell signaling. Major progress has been made in the management 
of ALL, especially with the introduction of multi agent chemotherapy by which, 
survival rate increased from 10% in the 1960s to almost 90% in 2000s.11,12   
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4. Prognostic factors of ALL  
Prognostic factors could be an indicator for considering the intensity of chemotherapy 
at diagnosis and the selection of patients in first remission for bone marrow 
transplantation. Major prognostic factors in ALL include the biologic and genetic 
features of leukemia cells, clinical features that are present at diagnosis and the early 
response to chemotherapy (Table 1).11  
 
In addition, circulating biomarkers have recently been emerging as important 
prognostic factors to predict the overall survival.13-16 Elevated serum LDH level at 
diagnosis has been consistently identified as an independent prognostic factor linked 
with poor survival.14,15,17 
 
Wulantingsih et al found inverse association between LDH and patient survival where 
higher pre-diagnostic LDH levels corresponded to lower cancer-specific survival 
following cancer diagnosis.17 Furthermore, there have been studies to indicate that 
the time to platelet recovery is an essential component of complete remission in acute 
lymphoblastic leukemia.16,18 Faderl et al showed the possibility of platelet recovery 
time as an independent prognostic factor to determine the disease free and overall 
survival.16 Also, lymphocyte recovery has been recently known to be a possible 
independent prognostic factor for overall survival of ALL.19,20 However, PKPD 
models of biomarkers to link and predict the disease progression of ALL and 
treatment efficacy have not been studied over. 
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Table 1. Known important prognostic factors in ALL in children 11 
Variable Favorable Unfavorable 
Clinical features 
Age (years) 1 < age < 10 1 > age ≥ 10 
Sex Female Male 
Initial white-cell count < 50,000 /mm3 ≥ 50,000 /mm3 
Biologic or genetic features of leukemia cells 
Immunophenotype B-cell T-cell 
Cytogenetic features 
ETV6-RUNX1, 
hyperdiploidy 
BCR-ABL1, 
hypodiploidy 
Early response to treatment 
Response to 1 week of 
glucocorticoid therapy 
Good response Poor response 
Bone marrow morphology after 1 
to 2 weeks of multi agent 
chemotherapy 
M1 marrow (< 5% 
blasts) by day 8 or 15 
No M1 marrow (≥ 5 % 
blasts) by day 8 or 15 
 
5. Study purposes 
The objective of the study is to develop a disease progression model, utilizing 
circulating biomarkers in pediatric patients with ALL. It is hypothesized that with 
(semi) mechanistic approaches, the developed disease progression models will 
increase the reliability of biomarkers in predicting disease dynamics. 
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II. MATERIALS AND METHODS 
 
1. Patients and data collections   
The study was conducted with retrospectively collected data from Severance Hospital, 
Seoul, Korea. Total of 74 patients’ data whom were diagnosed with ALL at the age 
of less than 20 were obtained from Electrical Medical Records. Patients with 
comorbidities were excluded in the study. It was a 52 week study, consisting of 
multiple cycles of chemotherapy before maintenance therapy and bone marrow 
transplantation during the treatment if necessary. Patients were dropped out from the 
study if they had relapses or deceased during the follow up. The study was approved 
by the Institutional Review Board of Severance Hospital.  
 
Three different biomarker candidates were first selected as possible endpoints for the 
analysis. Platelet count (PLT), LDH level and absolute lymphocyte count (ALC) were 
chosen according to literature search.12,13,15,16 However observations suggested that 
LDH lacked specificity in ALL thus it was excluded from the analysis (data not 
shown).  
 
Platelet count (PLT) and absolute lymphocyte count (ALC) at plasma level were the 
endpoints to be analyzed in this work. PLT were collected from a full red blood cell 
(RBC) count and ALC were collected from a full white blood cell (WBC) count. ALC 
were calculated from WBC counts and differential blood cell count percentages. RBC 
and WBC were assessed in the clinical laboratory of the Severance Hospital. 
Measurements were collected at the time of ALL diagnosis and up to 52 weeks after 
the diagnosis. 
１１ 
 
Blood samples for drug concentration were not available but the dosage information 
for each cycle was collected. Other laboratory results and hematological counts such 
as serum creatinine, uric acid and neutrophil count were collected. Disease status, 
demographic data such as age, gender and body weight were also collected as possible 
covariates.  
 
2. Model development   
ALC and PLT measured in plasma were analyzed by nonlinear mixed effects 
modeling. The model consisted of structure model and random effects model. The 
structure model would describe the typical patient level kinetics and dynamics of 
biomarkers. The random effects model would estimate inter patient variation and 
random unexplained variability such as measurement error. Four different structure 
models were proposed to describe the disease progression and treatment efficacy in 
patients with ALL in children and adolescents.  
 
A. Categorization  
To treat ALL, chemotherapy with multiple anticancer agents was proved to be more 
effective than monotherapy.21,22 Patients were stratified into two risk groups (standard 
and high risk). Criteria to stratify patients into risk groups were listed in Table 2. 
Depending on their initial risk, patients can receive slightly different combination of 
anticancer agents with different duration at each cycle. Treatments generally 
consisted of standard drugs such as prednisone, methotrexate, cytarabine, 
cyclophosphamide, vincristine and L-asparaginase. Unless the treatment toxicity was 
lethal, all patients received standard doses that were stratified by body surface area 
(BSA). Chemotherapy regimen consisted of 4 phases, induction, consolidation, 
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intensification and maintenance therapy. In addition to multi agent chemotherapy, 
some patients received cranial irradiation and/or bone marrow transplantation if 
appropriate.11,18 Study population were stratified according to risk groups for the 
analysis. 
 
Table 2. Risk stratification for ALL in children and adolescents  
Standard Risk 
- WBC counts are less than 50,000/μl or 
- Diagnosed at the age between 2 to 9 or 
- In the absence of CNS metastasis, mediastinal mass or 
- No t(9:22), biphenotypic leukemia and dupMLL 
arrangements 
High Risk 
- WBC counts are higher than 50,000/μl or 
- Diagnosed at the age less than 1 or over 10 or 
- Presence of CNS metastasis, mediastinal mass or 
- T-cell phenotype, t(9:22), biphenotypic leukemia and 
dupMLL arrangements or 
- Not achieved complete remission after remission 
induction therapy 
 
B. Baseline model for biomarkers  
Figure 1 and Figure 2 described the typical absolute lymphocyte count (ALC) and 
platelet count (PLT) prolife obtained from the ALL patients. Observed ALC at the 
diagnosis were above the reference range and decreased following the treatment. 
Decrease in ALC reflected the treatment related improvement in ALL, leading to a 
decrease in the synthesis rate of the ALC. Slight fluctuations and increase of ALC at 
the end of study period (after 250 days) despite the ongoing chemotherapy may 
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indicate the resistance effects. Unlike ALC, PLT was below the reference range at 
the diagnosis of ALL and the concentrations increases following the treatment. 
Increase in PLT reflected the treatment related improvement in ALL, leading to an 
increase in the synthesis rate of PLT. The fundamental assumptions in the model for 
each biomarker were as the followings:  
- The progression of the disease lead to increase in lymphocyte counts  
- Chemotherapy inhibit lymphocyte stimulation  
- The progression of the disease lead to decrease in platelet counts  
- Chemotherapy elicit platelet recovery 
 
The assumption was based on the observations as shown in Figure 1 and Figure 2. 
ALC and PLT profiles were described in two different form of turnover models, 
indirect response model 23 and proliferation model adopted from Friberg et al.24 
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Figure 1. Observations of mean value of ALC (*1000/mm3) over time (days) 
in ALL. 
 
 
 
 
 
 
 
 
Figure 2. Observations of mean value of PLT (*1000/mm3) over time (days) 
in ALL.   
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(1) Indirect response model  
ALC and PLT dynamics were described with indirect response models 23 in the forms 
of Equation 1 and Equation 2.  
𝑑𝐴𝐿𝐶
𝑑𝑡
 =  𝐾𝑖𝑛   × (1 − 𝐸𝑑𝑟𝑢𝑔)  − 𝐾𝑜𝑢𝑡  ×  𝐴𝐿𝐶(𝑡) Equation 1 
𝑑𝑃𝐿𝑇
𝑑𝑡
 =  𝐾𝑖𝑛   × (1 + 𝐸𝑑𝑟𝑢𝑔)  − 𝐾𝑜𝑢𝑡  ×  𝑃𝐿𝑇(𝑡) Equation 2 
 
Where 𝐾𝑖𝑛 is a zero order synthesis rate constant of biomarkers and 𝐾𝑜𝑢𝑡 is a first 
order degradation rate constant of biomarkers. Edrug, represents the drug effects and 
the main assumptions were that the drug effect decreases the synthesis rate of ALC 
(Equation 1) and increases the synthesis rate of PLT (Equation 2).  
 
(2) Proliferation cell model  
ALC and PLT dynamics were described with proliferation model to mimic the life 
span of both biomarkers from bone marrow production in Equation 3 - Equation 9 
below (Equation 3 applies to ALC, Equation 4 to PLT and the rest to both 
biomarkers). The structure model was adopted from Friberg et al.24 The schematic 
diagram of proliferation cell model was illustrated in Figure 3. The structure model 
comprised of five compartments where one compartment represented progenitor 
cells of biomarkers (Prol), three transit compartments with maturing biomarkers 
(Transit) and a compartment of circulating biomarkers observed in plasma.    
𝑑𝑃𝑟𝑜𝑙
𝑑𝑡
 =  𝐾𝑝𝑟𝑜𝑙 × 𝑃𝑟𝑜𝑙(𝑡) × (1 − 𝐸𝑑𝑟𝑢𝑔) × (
𝐶𝑖𝑟𝑐0
𝐶𝑖𝑟𝑐
)𝛾  − 𝐾𝑡𝑟  
×  𝑃𝑟𝑜𝑙(𝑡) 
Equation 3 
𝑑𝑃𝑟𝑜𝑙
𝑑𝑡
 =  𝐾𝑝𝑟𝑜𝑙 × 𝑃𝑟𝑜𝑙(𝑡) × (1 + 𝐸𝑑𝑟𝑢𝑔) × (
𝐶𝑖𝑟𝑐0
𝐶𝑖𝑟𝑐
)𝛾  − 𝐾𝑡𝑟  
×  𝑃𝑟𝑜𝑙(𝑡) 
Equation 4 
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𝑑𝑇𝑟𝑎𝑛𝑠𝑖𝑡1 
𝑑𝑡
=  𝐾𝑡𝑟  ×  𝑃𝑟𝑜𝑙(𝑡) −  𝐾𝑡𝑟  ×  𝑇𝑟𝑎𝑛𝑠𝑖𝑡1 Equation 5 
𝑑𝑇𝑟𝑎𝑛𝑠𝑖𝑡2 
𝑑𝑡
= 𝐾𝑡𝑟  ×  𝑇𝑟𝑎𝑛𝑠𝑖𝑡1 −  𝐾𝑡𝑟  ×  𝑇𝑟𝑎𝑛𝑠𝑖𝑡2 Equation 6 
𝑑𝑇𝑟𝑎𝑛𝑠𝑖𝑡3 
𝑑𝑡
= 𝐾𝑡𝑟  ×  𝑇𝑟𝑎𝑛𝑠𝑖𝑡2 −  𝐾𝑡𝑟  ×  𝑇𝑟𝑎𝑛𝑠𝑖𝑡3  
Equation 7 
𝑑𝐶𝑖𝑟𝑐 
𝑑𝑡
 =  𝐾𝑡𝑟  ×  𝑇𝑟𝑎𝑛𝑠𝑖𝑡3 − 𝐾𝑐𝑖𝑟𝑐  ×  𝐶𝑖𝑟𝑐  
Equation 8 
𝑀𝑇𝑇 =  
4
𝐾𝑡𝑟
 
Equation 9 
 
Kprol is a proliferation rate constant that determines the rate of proliferative cell 
divisions of progenitor cells of biomarkers. (
𝐶𝑖𝑟𝑐0
𝐶𝑖𝑟𝑐
)𝛾  mimicked the feedback 
mechanism from the circulating biomarkers to describe the rebound of biomarkers 
and Prol(t) is an amount of progenitor cells over time. It is assumed that the only loss 
of cells in the transit compartments is into the next compartment (Equation 5 - 
Equation 8). At steady state, 
𝑑𝑃𝑟𝑜𝑙
𝑑𝑡
= 0 thus Kprol is equal to rate constant Ktr. Friberg 
et al further assumed that Kcirc is equal to Ktr to minimize the number of parameters. 
For easier interpretation, the mean transit time (MTT) was estimated as shown in 
Equation 9 where n is the number of transit compartments. Edrug, represents the drug 
effects and the main assumptions were that the drug effect decreases the synthesis 
rate of ALC (Equation 3) and increases the synthesis rate of PLT (Equation 4).  
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Figure 3. The structural pharmacodynamics model describing the chemotherapy-
induced changes of biomarker proliferations adopted from Friberg et al.  
 
C. Drug effect model  
Due to a complex regimen to treat ALL, wide range of dose units and the fact that the 
standard dose of anticancer agents were used in each cycle, dose of each drug was set 
to 1 to describe the administration of chemotherapy. Each dose was generally 
standardized on the basis of BSA, the nominal dose of 1 was multiplied by the 
patient’s BSA then divided by the standard BSA (BSAstd), 1.73 m2 (Equation 10). 
Each dose was assumed to be administered with a dosing interval of 1 day. 
 
Drug concentrations were not available therefore K-PD approach was applied with 
theoretical allometry approach (Equation 11 and Equation 12). A(t) is the BSA 
standardized hypothetical drug amount of chemotherapy and K is the first order 
elimination rate constant with theoretical allometry approach as shown in Equation 
12. WT and WTstd is the weight of individual patient and standard weight of 70 kg 
respectively. Treatments were assumed to enhance or reduce the turnover rate of 
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biomarkers by the function Edrug, which was modeled to be either a linear function 
(Equation 14) or an Emax model (Equation 15). CE represents the hypothetic drug 
exposure to chemotherapy divided by nominal volume (WT/Wtstd) (Equation 13). 
Emax is the maximum inhibition effect and EC50 is the nominalized concentration 
which produced 50% maximum inhibition.   
 
D. Disease dynamics  
Three different disease latent approaches were used to describe the latent disease 
dynamics of ALL (D), with transit and circulating compartments as described in 
Equation 5 - Equation 9 being incorporated. First disease dynamic model was adopted 
from Buil-bruna et al 1 whose schematic diagram is shown in Figure 4 and model 
equations in Equation 16 - Equation 18.  
 
𝐷𝑂𝑆𝐸 =  1 ×  
𝐵𝑆𝐴
𝐵𝑆𝐴𝑠𝑡𝑑
 Equation 10 
𝑑𝐴
𝑑𝑡
=  −𝐾 × 𝐴(𝑡) Equation 11 
𝐾 = 𝐾𝑠𝑡𝑑 × (
𝑊𝑇
𝑊𝑇𝑠𝑡𝑑
)0.25 Equation 12 
𝐶𝐸 =   
𝐴(𝑡)
𝑉
 Equation 13 
𝐸𝑑𝑟𝑢𝑔 =  𝑆𝑙𝑜𝑝𝑒 × 𝐶𝐸 Equation 14 
𝐸𝑑𝑟𝑢𝑔 =  𝐸𝑚𝑎𝑥 ×  
𝐶𝐸
𝐶𝐸 + 𝐸𝐶50
 Equation 15 
𝑑𝐷
𝑑𝑡
  = α × 𝐷(𝑡) − 𝐸𝑑𝑟𝑢𝑔 Equation 16 
１９ 
 
 
 
 
 
 
 
 
 
Figure 4. The structural pharmacodynamics model describing the chemotherapy-
induced changes of biomarker proliferations with disease level adopted from Buil-
bruna et al and Friberg et al.  
 
Equation 16 defines the unperturbed dynamics of disease level of ALL. It describes 
that a natural history of ALL progress exponentially with the net growth rate of alpha 
(α). The disease level at diagnosis was set to 1 in all patients. Drug model (Edrug) 
was assumed to cause irreversible reduction on the net growth rate of ALL (Edrug = 
α × 𝐶𝐸 × 𝐷(𝑡)). Disease dynamics were then incorporated into proliferation cell 
model described in Equation 17 - Equation 18. Scaling constant (KD) and disease 
levels over time (D(t)) were added in the proliferative cell compartment. It was 
𝑑𝐴𝐿𝐶
𝑑𝑡
 = ((𝐾𝑝𝑟𝑜𝑙 ×  𝐴𝐿𝐶(𝑡))/(1 + K𝐷 × D(t))) × (
𝐶𝑖𝑟𝑐0
𝐶𝑖𝑟𝑐
)
𝛾
 − 𝐾𝑡𝑟  ×  𝐴𝐿𝐶(𝑡) Equation 17 
𝑑𝑃𝐿𝑇
𝑑𝑡
 = ((𝐾𝑝𝑟𝑜𝑙 ×  𝑃𝐿𝑇(𝑡)) × (1 + K𝐷 × D(t)) × (
𝐶𝑖𝑟𝑐0
𝐶𝑖𝑟𝑐
)
𝛾
 − 𝐾𝑡𝑟  ×  𝑃𝐿𝑇(𝑡) Equation 18 
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assumed that the disease level, D(t) increased the synthesis rate of the proliferative 
cells of ALC and decreased the synthesis rate of the proliferative cells of PLT.  
 
Second approach was adopted from Desmee et al 10 whose schematic diagram is 
shown in Figure 5 and model equations in Equation 19 - Equation 21.  
𝑑𝐷
𝑑𝑡
 = 𝑟 × (1 − 𝐸𝑑𝑟𝑢𝑔)𝐷(𝑡)) − 𝑑 × 𝐷(𝑡) Equation 19 
𝑑𝐴𝐿𝐶
𝑑𝑡
 = 𝐾𝑖𝑛 + 𝑝 × 𝐷(𝑡) −  𝐾𝑜𝑢𝑡 × 𝐴𝐿𝐶(𝑡) Equation 20 
𝑑𝑃𝐿𝑇
𝑑𝑡
 = 𝐾𝑖𝑛 + (
𝑝
(1 + 𝐷(𝑡))
) −  𝐾𝑜𝑢𝑡 × 𝑃𝐿𝑇(𝑡) Equation 21 
 
 
 
 
 
 
 
Figure 5. The structural pharmacodynamics model describing the chemotherapy-
induced changes of biomarker synthesis with disease level adopted from Desmee et 
al.   
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The model consisted of a separate compartment for disease level and the biomarker 
concentrations are described as turnover model. In the absence of treatment, the 
model assumed that the disease level (D) grows with the rate r and are eliminated 
with rate d (Equation 18). It is assumed that the chemotherapy for ALL (Edrug) acts 
by decreasing growth rate r. In the literature, Edrug was restricted to be between 0 
and 1. Increased disease level escalates biomarker level with a production rate (p), 
which is synthesized with endogenous zero order synthesis rate (Kin) and cleared from 
the plasma with first order elimination rate (Kout) .It is assumed that the disease level, 
D(t) increases the production of ALC and decreases the production of PLT (Equation 
20 and Equation 21). 
 
Lastly, Hansson et al was developed whose schematic diagram is shown in Figure 6 
and model equations in Equation 22 - Equation 25.  
 
 
 
 
 
 
 
 
Figure 6. The structural pharmacodynamics model describing the chemotherapy-
induced changes of biomarker proliferations with disease level adopted from Hansson 
et al and Friberg et al.    
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D(t) = 𝐴𝐿𝐶 × (1 + 𝐷𝑠𝑙𝑜𝑝𝑒 × 𝑡) Equation 22 
D(t) =
𝑃𝐿𝑇
(1 + 𝐷𝑠𝑙𝑜𝑝𝑒 × 𝑡)
 
Equation 23 
𝑑𝐴𝐿𝐶
𝑑𝑡
 = Kprol ×  D(t) × (1 − Edrug) × (
𝐶𝑖𝑟𝑐0
𝐶𝑖𝑟𝑐
)
𝛾
−  𝐾𝑡𝑟 × ALC(𝑡) 
Equation 24 
𝑑𝑃𝐿𝑇
𝑑𝑡
 = Kprol ×  D(t) × (1 + Edrug) × (
𝐶𝑖𝑟𝑐0
𝐶𝑖𝑟𝑐
)
𝛾
−  𝐾𝑡𝑟 × PLT(𝑡) 
Equation 25 
 
In this approach, disease progression model is used to determine the role of 
biomarkers as predictors of tumor dynamics.9 Hansson et al proposed that the disease 
progressions (D(t)) within untreated patients were described by a linear disease 
progression model dependent on time (t) with a slope parameter (Dslope) affecting the 
biomarker concentrations. It is assumed that the disease progression increases the 
synthesis rate of proliferative cells of ALC (Equation 24) and decreases the synthesis 
rate of proliferative cells of PLT (Equation 25). The disease dynamics are then 
incorporated into proliferation cell model described in Equation 24-25. Disease level 
is multiplied to Kprol to alter the synthesis rate of proliferative cells of biomarkers. 
 
E. Chemotherapy resistance 
Treatment resistance term was included in the chosen basic disease progression 
model to account for the resurgence in circulating biomarker levels observed in the 
dataset. It was assumed that the treatment resistance was in relation to the cumulative 
chemotherapy exposure or the area under concentration curve (AUC) for the 
hypothetical effect-site concentration (CE) (Equation 13). Equation 26 describes the 
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AUC for CE from zero to each evaluation time point. Three different approaches were 
taken to describe the drug treatment resistance.  
 
First the exposure was assumed to decrease exponentially with the scale parameter 𝛾 
as shown in Equation 27. The other approach assumed that tolerance develops in 
proportion to CE and disappears in the first order resistance development constant 
(KR) as shown in Equation 28. Then the tolerance effect was applied as inhibiting the 
drug effect as shown in Equation 29. In addition, extra Imax drug model (Equation 30) 
representing the tolerance effect was subtracted from the drug effect as shown in 
Equation 31. Resistance effect was only described with the selected basic disease 
progression model that best described the data. 
 
 
 
𝐴𝑈𝐶 = ∫ 𝐶𝐸(𝑡) Equation 26 
𝑅 = 𝑒−𝛾×𝐴𝑈𝐶 Equation 27 
𝑑𝑇𝑂𝐿
𝑑𝑡
 = 𝐾𝑅 × 𝐶𝐸 − 𝐾𝑅 ×  𝑇𝑂𝐿 Equation 28 
𝐸𝑑𝑟𝑢𝑔 =
𝐸𝑚𝑎𝑥 ×  
𝐶𝐸
𝐶𝐸 + 𝐸𝐶50
(1 + 𝑇𝑂𝐿)
 Equation 29 
𝑅𝑑𝑟𝑢𝑔 =  𝑅𝐼𝑚𝑎𝑥 ×  
𝑇𝑂𝐿
𝑇𝑂𝐿 + 𝑅𝐼𝐶50
 Equation 30 
𝐸𝑑𝑟𝑢𝑔 = 𝐸𝑚𝑎𝑥 ×  
𝐶𝐸
𝐶𝐸 + 𝐸𝐶50
− 𝑅𝑑𝑟𝑢𝑔 Equation 31 
２４ 
 
F. Covariate analysis 
Parameter-covariate relationships were graphically and statistically tested 
preliminarily with the basic disease progression model. The selection procedure was 
conducted separately for each biomarker. A stepwise covariate model building 
approach (SCM) was performed afterward using PsN at significance levels of p < 
0.05 for forward selection and p < 0.01 for backward elimination.25 The criteria of the 
statistical test were based on the χ2-distribution.26 
 
Potential covariates were searched based on previous studies where its relevance to 
biomarker levels or ALL were clinically known or had been studied and proven to be 
important. Those included demographic factors such as age and gender and laboratory 
results such as serum creatinine, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT) and uric acid.11,27-30 AST and ALT were included in the 
covariate analysis, largely to evaluate the impact of liver and hepatic dysfunction on 
chemotherapy efficacy. 
 
G. Overall survival analysis   
Different distributions (constant, log-logistic, weibull and gompertz) were evaluated 
to describe the baseline hazard. Predicted latent disease progression slopes at day 30 
from PLT disease progression models (i.e., 𝐷𝑠𝑙𝑜𝑝𝑒 in Equation 22) and mean ALC 
ratio to baseline predicted from ALC disease progression model were introduced as 
covariates.  
Where h0(t) it the baseline hazard, δ is the parameter to be estimated and Bi is a set 
of possible predictors of survival time in each individual, i. Possible predictors are 
ℎ(𝑡) = ℎ0(t) ×  𝑒
𝛿×𝐵1  Equation 32 
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the estimated parameters from circulating biomarker disease progression models and 
the history of bone marrow transplantation and age at diagnosis.  
 
H. Estimation method  
All PKPD analyses were done with NONMEM (Version 7.3, ICON, Hanover, MD) 
and the first order conditional estimation with the interaction option. Survival model 
was analyzed with the first order method. Visual predictive checks (VPCs) were 
created using Wings for NONMEM 740. PsN version 3.4.2 and Xpose implemented 
in R was used for SCM and graphical representation  
 
3. Model selection and evaluation  
Model selection was guided by the precision of parameter estimates, objective 
function value (OFV) and Akaike Information criterion (AIC). To verify that the final 
population PKPD models adequately described the central tendency and spread of the 
data, the models were evaluated using a goodness of fit plots and VPC plots given 
1,000 simulated datasets from the final models. Observed biomarker concentrations 
were overlaid with model predictions (mean, 5th and 95th percentiles) to detect the 
fraction of the data that lay within the model prediction intervals.31 Kaplan-Meier 
VPC plots were plotted to evaluate the survival analysis model.32     
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III. RESULTS  
 
1. Patient demographics and data  
Data were available from 74 children and adolescents who were diagnosed with ALL 
for disease progression model. A summary of the demographic characteristics of 
study population is reported in Table 3. For K-PD approach, there were 7429 data 
points of drug administration. A mean of 100 dosing points were taken from each 
patient (range 31 to 201). There were 2810 measurements of ALC and 2840 
measurements of PLT. On average, each patient contributed 38 points on average for 
both ALC and PLT (range 19 to 56 and 20 to 57 for ALC and PLT respectively).  
 
Table 3. Demographic characteristics of study subjects for population PK analysis 
Biomarkers Dataset (n=74) 
ALC 1 (*1000/mm3) 157±54.1 
PLT 1 (*1000/mm3) 1.02±0.39 
Continuous  
Age at diagnosis 1 (years) 6.3±3.79 
Weight 1 (kg) 24.8±13.6 
AST 1 (IU/L) 42.3±24.3 
ALT 1 (IU/L) 58.76±35.6 
Creatinine 1 (mg/dL) 0.44±0.13 
Uric acid1 2.27±3.06 
Categorical   
Gender (Y/N) 37/37 
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Risk group (Standard/High) 26/48 
Bone marrow transplantation (Y/N) 38/36 
1 Values are expressed as mean±SD 
 
2. PKPD modeling of ALC   
Represented model in Figure 6 best described the dynamics of ALC in plasma over 
time. Different approaches for disease dynamics provided poorer fit to the data in 
terms of graphical analysis and AIC. The core assumption of this model is that the 
disease linearly progress with time, the disease dynamics will increase the synthesis 
of ALC and drug treatment will reduce the effect of disease progression. Addition of 
chemotherapy resistance further improved the fit graphically where extra Imax drug 
model was added to account for the reduced efficacy (Equation 30) and chosen as a 
final basic model to describe the disease progression with ALC. SCM was carried out 
and age was chosen as significant covariates to explain the variability of mean transit 
time of lymphocyte maturation from bone marrow to plasma. In addition, white blood 
cell count (WBCC) was selected to describe the uncertainty in ALC at baseline 
progenitor cells where the baseline decreases with age over 5.11 years. No covariates 
were deleted from backward deletion and no other relationships that were tested in 
SCM showed statistical significant effects.   
 
The AIC value of the selected model was -244.056 where the graphical fit was the 
best out of all the tested models. The OFV of final disease progression model was -
286.056 and the significance of P-value from basic model was < 0.0001 (∆OFV: 
34.785). Data supported the estimation of between subject variability for baseline, 
Emax, EC50, mean transit time (MTT), disease slope and drug half-life estimated from 
the PKPD model. Between subject variability ranged from 31.3% to 242.7%, 
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reflecting the high heterogeneity of the data. Proportional error model best described 
the residual unidentified variability in the data. 
 
The estimated disease progression model parameters for ALC are listed in Table 4. 
Estimated EC50 is 0.00026 for standard risk group and 0.711 for high risk group. 
Estimated slope to describe the linear progression of the ALL that affects the 
synthesis rate of proliferation cells of ALC is 0.00003 per day. Estimated KR is 
0.0203 per day indicating the rather slow onset of chemotherapy resistance of about 
49.3 days. A goodness of fit plot of the selected final model is drawn in Figure 7 and 
shows that the model is in a relatively good agreement with the data.  
 
The disease progression model of ALC was evaluated by VPC. The confidence 
interval of the ALC predictions was consistent with the median observations (Figure 
8). To further evaluate the appropriateness of the model, the selected disease 
progression model was compared to the model without disease progression slope as 
shown in Figure 8. A VPC using a model with the slope of disease progression fixed 
to 0 were almost same at predicting the upper quartile but was worse at predicting the 
median. Overall, the model with disease slope parameter was better at describing the 
time course of ALC especially at the median and lower quartiles.  
 
Table 4. Estimated parameters of disease progression of ALC (*1000/mm3) before 
maintenance therapy 
OFV (AIC) -286.056 (-244.056) 
No. of Parameter 21 
Parameter Structural parameters (RSE(%)) 
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Baseline (103/mm3) 1.81 (10.6) 
Covariate: WBCC 0.173 (5.8) 
Emax* 0.125 (11.6) 
SR_EC50* 0.00026 (146.9) 
HR_EC50* 0.711 (36.7) 
MTT (day) 5.34 (5.1)- 
Covariate: Age 0.0818 (27.8) 
𝜸 0.0973 (11.3) 
Disease slope (/day) 0.00003 (37.3) 
T half life (day) 18.8 (22.4) 
KR (/day) 0.0203 (58.1) 
TImax* 0.0191 (33.5) 
TIC50
* 0.112 (188.4) 
Parameter Between subject variability (RSE(%)) 
ω Baseline (CV(%)) 52.5 (13.6) 
ω Emax(CV(%)) 31.3 (19.2) 
ω EC50(CV(%)) 140.7 (20.6) 
ω MTT(CV(%)) 242.7 (16.2) 
ω Disease slope (CV(%)) 109.1 (23.8) 
ω T half life (CV(%)) 122.9 (18.4) 
Parameter Residual variability (RSE(%)) 
σ Proportional (CV(%)) 62.3 (1.6) 
*: unitless variables as real dosing information was not used and hypothetical amount 
was applied instead.   
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Figure 7. A goodness of fit plot for the final model of ALC where CWRES represents 
conditional weighted residual and population predictions represents the model 
predictions. 
 
 
 
 
 
 
Figure 8. VPC plots of disease progression model of ALC (right) and the same model 
without a disease progression term (left). Observations and predictions are illustrated 
in red lines and black lines respectively. Solid lines represent median, lower and 
upper dashed lines represent 5th percentile and 95th percentile respectively. Shaded 
areas describe 95% confidence interval of the predictions.  
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3. PKPD modeling of PLT  
Represented model in Figure 6 best described the dynamics of PLT in plasma over 
time and was selected as a final basic model. The core assumption of this model is 
that the disease progress linearly with time and the disease dynamics will decrease 
the synthesis of PLT and drug treatment will reduce the effect of disease progression. 
Addition of chemotherapy resistance further improved the model fit when extra Imax 
drug model was added to account for the reduced chemotherapy efficacy due to 
resistance (Equation 30) and chosen as a final basic model to describe the disease 
progression with PLT. SCM was carried out and ALT, AST and creatinine was 
chosen as significant covariates to explain the variability of drug half-life for K-PD 
model. In addition, age was selected to describe the uncertainty in platelet counts at 
baseline where the baseline increases if the patient is over 5.24 years. No covariates 
were deleted from backward deletion and no other relationships that were tested in 
SCM showed statistical significant effects.   
 
The AIC value of 28295.284 for the selected model was the lowest which 
demonstrated that the chosen model best described the data. The OFV of final disease 
progression model was 28249.284 and the significance of P-value from basic model 
was < 0.0001 (∆OFV: 150.098). Between subject variability for baseline, Emax, EC50, 
mean transit time (MTT), disease slope and drug half-life were estimated. Between 
subject variability ranged from 27.9% to 160.3%, reflecting the high dispersion of the 
data. Proportional error model best described the residual unidentified variability in 
the data.  
 
The estimated disease progression model parameters for PLT are listed in Table 5. 
Estimated EC50 of standard risk group is 1.02 and 3.1 for high risk group. Slope to 
describe the linear progression of the disease that affects the synthesis rate of 
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proliferation cells of PLT is 0.0000671 per day. Estimated KR is 0.0912 per day 
indicating the rather fast onset of chemotherapy resistance of about 11.0 days. A 
goodness of fit plot of the selected final model is drawn and the plots is in a relatively 
good agreement with the data (Figure 9). 
 
The disease progression model of PLT was evaluated by VPC. The confidence 
interval of the PLT concentration predictions was consistent with the median 
observations (Figure 10). The model seemed to capture the overall shape and the 
dispersion of the data well except upper quartiles. To further evaluate the 
appropriateness of the model, the selected disease progression model was compared 
to the model without disease progression slope (Figure 10). A VPC using a model 
with the slope of disease progression fixed to 0 was not so markedly different but 
nevertheless, the model with disease slope parameter was better at describing the time 
course of PLT especially at the upper quartiles with narrower confidence intervals.  
 
Table 5. Estimated parameters of disease progression of PLT (*1000/mm3) before 
maintenance therapy 
OFV (AIC) 28249.284(28295.284) 
No. of Parameter 23 
Parameter Structural parameters (RSE(%)) 
Baseline (103/mm3) 62.8 (15.5) 
Covariate:Age 0.173 (93.1) 
Emax* 1.02 (14.3) 
SR_EC50* 1.57 (39.4) 
HR_EC50* 3.1 (33.2) 
MTT (day) 17 (2.3) 
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𝜸 0.215 (5.0) 
Disease slope (/day) 0.0000671 (52.2) 
T half life (day) 29.9 (3.2) 
Covariate: AST1 0.0192 (10.3) 
Covariate: AST2 0.0347 (21.3) 
Covariate:ALT -0.335 (16.4) 
Covariate: Creatinine 0.135 (131.1) 
KR (/day) 0.0912 (23.1) 
TImax* 0.738 (19.4) 
TIC50* 3.13 (17.9) 
Parameter Between subject variability (RSE(%)) 
ω Baseline (CV(%)) 67.3 (13.5) 
ω Emax(CV(%)) 13.9 (24.5) 
ω EC50(CV(%)) 100.5 (24.4) 
ω MTT(CV(%)) 27.9 (14.2) 
ω disease slope (CV(%)) 160.3 (20.2) 
ω T half life (CV(%)) 122.9 (17.5) 
Parameter Residual variability (RSE(%)) 
σ Proportional (CV(%)) 57.8 (2.0) 
*: unitless variables as real dosing information was not used and hypothetical 
amount was applied instead.   
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Figure 9. A goodness of fit plot for the final model of disease progression of PLT 
where CWRES represents conditional weighted residual and population predictions 
represents the model prediction 
 
 
 
 
 
 
 
Figure 10. VPC plots of disease progression model of PLT (right) and the same 
model without a disease progression term (left). Observations and predictions are 
illustrated in red lines and black lines respectively. Solid lines represent median, 
lower and upper dashed lines represent 5th percentile and 95th percentile respectively. 
Shaded areas describe 95% confidence interval of the predictions. 
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4. Overall survival analysis  
A constant hazard model best described the underlying baseline hazard distributions 
of 3 year overall survival of ALL patients. Predicted latent disease slope of PLT at 
day 30 (DPLT) and predicted ALC ratio to baseline averaged over the period of day 1 
to day 22 (RALC) were statistically significant predictors of overall survival. Inclusion 
of history of bone marrow transplantation (BMT) further improved the model fit, in 
terms of OFV (Equation 34). Inclusion of these covariates decreased the likelihood 
by 23.372 points. 
 
Predicted latent disease slope of ALC at day 30 (DALC) was a significant predictor 
of overall survival when tested individually but was no longer significant when 
other predictors were included in the model. Estimated parameters for overall 
survival analysis are reported in Table 6. Increases in latent disease slope of PLT 
and ALC ratio smaller than 0.8 were associated with an increased mortality. 
Performance of BMT further increased the risk of death.  
 
The VPC of the survival model with a Kaplan-Meir plot with the simulated 95% 
confidence interval shows good predictive performance (Figure 11).  
 
 
 
ℎ0(t) = λ Equation 33 
ℎ(𝑡) = ℎ0(t) ×  𝑒
𝛿1×𝐷𝑃𝐿𝑇+𝛿2×𝑅𝐴𝐿𝐶+𝛿3×𝐵𝑀𝑇 Equation 34 
３６ 
 
Table 6. Model parameter estimates for 3 year overall survival of ALL patients  
OFV 127.885 
No. Parameter 4 
Structural Parameters (RSE(%)) 
λ (/month) 0.0173 (105.2) 
δ1 25.7 (14.9) 
δ2 1.87 (32.5) 
δ3 -2.91 (47.4) 
Variance Parameters 
ω (CV%) 0 FIX 
 
 
 
 
 
 
 
 
Figure 11. Kaplan-Meier plot of overall survival data. Observations are illustrated in 
blue lines and shaded areas describe 95% prediction intervals of the Kaplan-Meier 
plot. Base hazard was described by a constant model (λ=0.0173) and applied in the 
simulations.   
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IV. DISCUSSION  
Novel serum biomarkers have been emerging as promising predictive value in 
relations to oncology.1,33 Development of mechanistic models are particularly 
important to characterize the time course of biomarkers since the relations between 
biomarker concentrations and disease progression are often not be linear and 
straightforward.1 
 
ALC and PLT are frequently measured in routine practice and there have been many 
studies that published the importance of ALC and PLT as important prognostic 
factors.12,13,16,18,20,34,35 Published studies generally used one or two time points to 
review the role of biomarkers as a significant predictor in ALL. Rabin et al reviewed 
ALC at several time points during induction therapy and concluded that the patients 
with ALC higher than 1,500 cells/μl at day 29 had a superior 6-year relapse free 
survival and overall survival.20 Zeidler et al on the other hand focused the relevance 
of normal blood counts during early treatment phase of ALL. The study found that 
the platelet count on treatment day 33 after induction therapy significantly associated 
with treatment outcome.18 Our study focused on the time course of ALC and PLT 
instead of few time points as there are no studies that analyzed the predictive value 
of longitudinal data of ALC and PLT in relations to clinical outcomes of ALL.  
 
Selected disease progression models are capable of describing the longitudinal data 
of ALC and PLT in a biological manner where the maturation of biomarker from the 
bone marrow to the plasma is described by semi-mechanistic model adopted from 
Friberg et al.24 In addition, disease progression of ALL is described to directly affect 
the synthesis of proliferative cells in the bone marrow as ALL is a malignant disease 
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of the bone marrow where early lymphoid precursors proliferate and replace the 
normal hematopoietic cells of the marrow.  
 
In this study, it is assumed that the disease progression increases the synthesis of 
lymphocyte proliferative cells and decreases the synthesis of platelet proliferative 
cells as the early clinical symptoms include thrombocytopenia and raised WBC 
counts 11. These assumptions are rather crude to describe the complex biological 
processes of maturation of selected biomarkers but it is believed that they will be 
sufficient to capture the major process influencing longitudinal data of biomarkers. 
Estimated slope of disease progression on proliferation rate of biomarkers is 0.00003 
per day and 0.0000671 per day for ALC and PLT respectively. The estimated values 
are rather small but the findings are important that the evolving disease clearly affects 
the proliferation rate of biomarkers in bone marrow.  
 
In the model, a reduction or progression of ALL is reflected in a change of biomarker 
concentrations. Chemotherapy is considered to directly influence production of 
lymphocyte and platelet in the bone marrow which indirectly effects the 
concentrations at plasma. Estimated EC50 of chemotherapy for ALC and PLT are 
higher in the high risk group than the standard risk group. Risk groups are stratified 
according to the known prognostic factors of ALL (Table 2) and that a patient is 
classified to a severe risk group (ie. High risk) if the known prognostic factors such 
as WBC and age are unfavorable.11 As a result, estimated parameter results from the 
models are in accordance with findings from a previously published studies regarding 
ALL11 where higher estimated value of EC50 indicate more complex regimen of 
chemotherapy are required or that the ALL is more persistent and takes longer for the 
treatment to be effective.  
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Development of chemotherapy resistance is described in the terms of inhibitory Imax 
model that reduces the overall efficacy of Emax drug model over time. Half-life to 
develop chemotherapy resistance is estimated to be about 49.3 days in ALC and 
estimated Imax is 0.0129 which is about 10 times lower than the estimated Emax of drug 
model. These findings can be an indication that the drug resistance may only hinder 
up to 10% of maximum treatment effect which could be due to multiple use of 
cytotoxic drugs.11,21,35 However in terms of PLT, half-life to develop chemotherapy 
resistance is estimated to be about 11.0 days and estimated Imax is 0.738 which can 
inhibit up to 70% of estimated Emax of drug model. These findings can be an indication 
that the drug resistance may be exhibited more quickly through PLT than ALC.  
 
AST, ALT and creatinine were shown to affect the half-life of chemotherapy 
treatment in PLT which is consistent with literature where impaired liver or renal 
function may change the metabolism and/or elimination of drugs from the body.28,34,36 
Age is a significant covariate to explain variability in baseline of biomarker PLT and 
mean transit time of ALC. It is expected as age is a proven prognostic factor of ALL 
and influence the baseline value or maturation time of biomarkers which can possibly 
be an indirect marker of ALL progression.11,18,20  
 
The data was generally representative of ALL patients in children and adolescents as 
the survival rate of current dataset (83%) was similar to the reported survival rate in 
the literature.11 Attempts to predict overall survival based on changes in biomarker 
concentrations showed that the model-predicted parameters or biomarker responses 
in PLT and ALC based on longitudinal data can be used as an additive tool to monitor 
disease in ALL patients in children and adolescents. The findings can be supported 
by the published literature where the time to platelet recovery from thrombocytopenia 
and ALC ratio at day 29 were shown to be important predictors of overall survival.16,20 
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For the developed model, since longitudinal data of ALC were applied, mean ALC 
ratio over day 1 to day 22 was sufficient to be a powerful predictor of 3 year survival 
of ALL patients in children and adolescents.  
 
Developed models in this project have several limitations. First of all, the treatment 
options from gathered patients were very heterogeneous and patients in high risk 
group were presented with genetic variations. Further work should be carried out to 
subset high risk group according to genetic variations. Treatment effect was 
established through K-PD model due to lack of pharmacokinetic data and this may 
mask the possible interactions between anticancer agents and individual exposure 
variability of drugs. In addition, the predictive performance of the disease progression 
model may vary in the clinical settings where individual patient’s characteristics vary 
greatly but addition of covariates in the model could be sufficient to explain the 
variability. External validation should be carried out in further studies to evaluate the 
performance capability of the developed models. Another limitation is that due to the 
nature of data recollection from clinical setting, maintenance therapy period could 
have been included in some of the patients from few days up to few weeks. However, 
intensity of the biomarker measurements were sparse towards the maintenance 
therapy and must not have impacted the results to build the biomarker disease 
progression models.   
 
Despite its limitations, the study developed a modeling framework that allowed 
integration of the time course of circulating biomarker responses during disease 
progression. In addition, predicted biomarker responses were shown to be important 
predictors of survival time in ALL patients in children and adolescents. The 
framework approach does not only enables predictions of survival time for further 
use within other pediatric ALL patients but can also be applied to other indications.   
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V. CONCLUSION  
Emax model with K-PD theoretical allometry approach, inhibitory Imax model of 
development of chemotherapy resistance, proliferation model of biomarkers and 
linear disease progression on synthesis rate of proliferative cells adequately describe 
the longitudinal data of ALC and PLT in children and adolescents with ALL. 
Predicted latent disease slope of PLT, predicted mean ALC ratio to baseline and 
history of BMT were found to be the most promising variables as predictors of 
survival time of ALL patients. It is believed that the modeling circulating biomarkers 
could be a useful tool to monitor disease of ALL in children and adolescents.   
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ABSTRACT (IN KOREAN)  
소아청소년 항암치료에서 바이오마커기반 질병진행 예측모형 개발 
< 지도교수 박 경 수 > 
연세대학교 대학원 의과학과 
허영아 
목적  
본 연구의 목적은 급성 림프구성 백혈병 소아 환자들에게서 바이오마커 
기반 질병진행을 예측할 수 있는 모형을 모델링 하고 모델 매개변수 
추정치와 환자의 공변량을 이용하여 환자의 생존 기간을 예측하여 향후 
환자 개인별 특성을 고려한 급성 림프구성 백혈병 환자의 질병관리 또는 
적절한 항암요법을 선택하는데 활용하고자 한다. 
방법 
본 연구는 후향적 연구로서 2000 년 1 월 1 일 ~ 2015 년 7 월 31 일의 
기간 동안 연세의료원 세브란스병원에서 급성 림프모구 백혈병 
소아암으로 진단받고 치료받은 환자들의 전자의무기록 (electronic 
medical record, EMR) 에서 수집된 총 74 명의 자료를 분석하였다. 유효성 
평가를 위한 biomarker 은 기존 연구에서 급성 림프모구 백혈병 
예후인자로 알려진 혈소판 및 림프구 수치를 사용하였다. 질병이 
진행됨에 따라 혈소판은 감소하고 림프구는 증가한다는 가정하에 
항암치료 효과는 disease progression model 로 모델링 하였다. 공변량 
분석에는 stepwise 방법을 사용하여 환자의 나이, 백혈구 수, creatinine, 
AST, ALT 등의 유의성을 평가하였으며 forward inclusion 과 backward 
elimination 의 유의도는 각각 0.05 와 0.01 로 설정하였다 37. 
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자료의 분석 및 모형 구축에는 비선형혼합효과 모델링에 기반을 둔 
NONMEM 7.3 version (ICON Development Solutions, MD)이 사용되었으며 
필요에 따라 Wings for NONMEM, Perl-Speaks-NONMEM (PSN), R 등의 
프로그램이 사용되었다.  
개발된 모형의 평가는 Visual predictive check (VPC) 를 통한 시뮬레이션 
자료와 실제 자료 사이의 유사성으로부터 모형의 예측능력을 확인하는 
것으로 진행하였다.31 아울러 생존 모형은 각 시간에서의 환자의 실제 
생존 여부와 모형에서 예측된 생존 확률를 시각적으로 비교하는 것으로 
평가하였다.32  
결과  
74 명의 환자들은 임상에서 쓰이는 예후인자에 따라 고위험 (HR)과 
표준위험 (SR) 그룹으로 나뉘었다. 개발된 질병진행 모델은 K-PD 모형의 
속도상수, 항암제 효능 (Emax 모델로 구현), 바이오마커의 성숙도 (transit 
모델로 구현) 그리고 질병진행 상수 등의 파라미터로 구성되었다. 
항암치료 효과는 K-PD 모형으로 약물 노출량을 얻은 후 이것을 바탕으로 
약물 효과를 Emax 모델로 구축하였다. 얻어진 EC50 파라미터의 값은 
ALC 와 PLT 모두 저위험군에 비해 고위험군이 더 높았다. 바이오마커의 
성숙에 걸리는 시간 (MTT) 은 림프구는 5.34 일, 혈소판은 17.0 일로 
알려져 있는 life span 일수와 비슷하였다. 또한 바이오마커의 생리학적 
기전을 반영하기 위해 feedback mechanism 을 적용하였는데. 모델에서는 
바이오마커의 증식이 질병의 진행에 따라 변할 수 있고 혈중에서 얻어진 
바이오마커의 농도는 그에 반비례하다고 추정하였다. Feedback 
mechanisms 에서 구해진 gamma 값은 ALC 는 0.0973, PLT 는 0.215 로 
PLT 의 피드백이 좀 더 급변하는 것으로 결과가 나왔다. 공변량 분석을 
진행한 결과, WBCC 가 ALC 의 baseline 에 관여하는 것으로 발견 되었고 
나이 또한 림프구의 성숙도에 관여하는 것으로 모델링 되었다. 또한 AST, 
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ALT, creatinine 이 PLT 관련 항암치료약물 반감기에 영향을 주는 것으로 
발견되었고 추후 나이가 PLT 의 baseline 에 영향을 주는 것으로 
발견되었다. 그 후 질병진행 속도의 30 일 시점에서의 모델 예측치, BMT 
과거력, 그리고 ALC 의 22 일 시점까지의 모델 예측치와 baseline 간의 
비의 평균값을 공변량으로 대입하여 생존률 예측모형을 개발하였다.  
결론  
본 결과는 바이오마커를 통하여 급성 림프모구 백혈병의 질병 진행 
정도를 예측하고자 하였다. 개발된 바이오마커 질병 진행 예측 모델은 
예측치가 관측치와 대체로 일치하였다. 또한 질병 진행 예측 모델을 통해 
얻은 파라미터들을 사용하여 개발된 생존모형은 관측된 생존률을 잘 
예측하였다. 본 연구는 바이오마커 기반의 질병 진행 예측 모델이 급성 
림프모구 백혈병 환자의 질병관리에 활용할 수 있음을 보여준다.  
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